Medical Science Liaison

This job posting is no longer active

Updated: September 9, 2019
Location: Dallas, TX, United States
Job ID: 4254


tsp, a Syneos Health company, is engaged in a direct hire search for Biohaven Pharmaceuticals.  Biohaven is currently building a MSL team.  As a member of the field-based medical affairs team, this position will function as an extension of the Medical Affairs organization and will be responsible for developing and managing professional relationships with medical thought leaders involved in various stages of product development and medical organizations including treatment centers, established societies and associations.


  • Develop & maintain relationships with key scientific centers and leaders within Neurology/Migraine
  • Scientifically Engage with high priority HCP’s and patient advocacy groups, Pre and Post Launch
  • Deliver clinical/scientific information to varied audiences with effect.
  • Support community Affairs and general program mgmt.
  • Support payer access clinical strategies

Job Requirements

  • NP/PA/MSN but PhD, PharmD or MD preferred
  • 2+ years’ experience as an MSL or related neurology research or medical affairs experience
  • Excellent Communication and Scientific affiliation
  • CNS experience required, Migraine preferred
  • Product launch experience preferred
  • Possess a valid driver's license to drive to assignments, unless otherwise specified
  • 50-60% Travel

Biohaven is a clinical-stage biopharmaceutical company developing a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. Biohaven is guided by proven leadership from industry and academic settings with strong support from top-tier biopharma investors.

Biohaven is utilizing an entrepreneurial organizational structure that minimizes hierarchy combined with deep experience in drug development to leverage a range of intellectual property licensed from companies and institutions that include Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital.

Since our establishment in 2013, and especially since our initial public offering in 2017, we have made rapid progress with multiple compounds across our CGRP receptor antagonist and glutamate modulator platforms. Today, we are ready to achieve a number of new clinical and regulatory milestones, including an NDA filing in 2019 for rimegepant our novel, orally-dosed migraine treatment. We also have a July 2019 PDFUA date for BHV-0223, our novel, sublingual formulation of riluzole for patients with ALS.

Syneos health and its clients are affirmative action/equal opportunity employers (Minorities/Females/Vets/Disabled)

Click here to enable personalized experience


Inside Syneos Health

Tell Us About Your Candidate Experience! Get In Touch